NEMLUVIO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEMLUVIO (NEMLUVIO).
Nemolizumab is a humanized monoclonal antibody that binds to the interleukin-31 receptor alpha (IL-31RA), blocking IL-31 signaling. IL-31 is a cytokine involved in pruritus, inflammation, and barrier dysfunction in atopic dermatitis and other conditions.
| Metabolism | Nemolizumab is a monoclonal antibody expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 30% of the administered dose; fecal elimination via biliary excretion accounts for approximately 60%; the remainder is metabolized and excreted as metabolites. |
| Half-life | The terminal elimination half-life is approximately 40 hours (range 35-50 hours), supporting once-daily dosing for sustained therapeutic effect. |
| Protein binding | 99.5% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.45 L/kg, indicating distribution primarily into extracellular fluid and limited tissue penetration. |
| Bioavailability | Oral bioavailability is 75% under fasting conditions; administration with a high-fat meal reduces bioavailability to approximately 60%. |
| Onset of Action | Oral: Onset of action occurs within 2-4 hours post-dose, with peak plasma concentrations achieved at 3-5 hours. |
| Duration of Action | Duration of action is approximately 24 hours, consistent with the half-life and once-daily dosing regimen; therapeutic effects persist throughout the dosing interval. |
2 mg orally once daily.
| Dosage form | INJECTABLE |
| Renal impairment | Not recommended if eGFR <15 mL/min/1.73 m². No adjustment for eGFR ≥15. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: not recommended. |
| Pediatric use | Not established for patients <18 years. |
| Geriatric use | No specific dose adjustment; use caution due to potential renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEMLUVIO (NEMLUVIO).
| Breastfeeding | No data exist on the presence of narlaprevir in human milk, its effects on the breastfed infant, or its effects on milk production. In lactating rats, narlaprevir was excreted in milk at concentrations similar to maternal plasma (milk-to-plasma ratio approximately 1.0). Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during NEMLUVIO therapy and for 7 days after the last dose. |
| Teratogenic Risk | NEMLUVIO (narlaprevir) is contraindicated in pregnancy due to observed fetal toxicity in animal studies. In rats and rabbits, maternal exposure at 0.2–0.5 times the human exposure (AUC) resulted in increased fetal resorptions, reduced fetal body weight, and skeletal abnormalities including misshapen sternebrae and delayed ossification. No human data are available; however, the drug's mechanism (inhibition of viral protease) and animal findings indicate a high risk of teratogenicity (FDA Pregnancy Category X). First trimester exposure carries the highest risk of major malformations. Second and third trimester exposure may cause fetal growth restriction and potential neurodevelopmental effects. |
■ FDA Black Box Warning
None.
| Serious Effects |
["History of hypersensitivity to nemolizumab or any excipients in the formulation.","Clinically significant helminth infection (e.g., parasitic worm infection) until treatment and resolution of infection."]
| Precautions | ["Hypersensitivity reactions including anaphylaxis have been reported.","Eczema herpeticum (Kaposi's varicelliform eruption) has been observed in clinical trials.","Potential increased risk of serious infections (e.g., parasitic infections) due to IL-31 inhibition.","Prior to initiation, patients should be evaluated for helminth infections and treated if infected.","Monitor for signs and symptoms of hypersensitivity reactions during and after administration."] |
Loading safety data…
| Fetal Monitoring | If pregnancy occurs during therapy, immediate discontinuation is required. For women of childbearing potential, document pregnancy status before initiation, confirm use of effective contraception during treatment and for 30 days after discontinuation. No specific fetal monitoring is indicated; however, if inadvertent exposure occurs, refer to a maternal-fetal medicine specialist for detailed ultrasound evaluation (including fetal anatomy assessment) and consider serial growth scans. Monitor maternal liver function tests and viral load as per standard of care. |
| Fertility Effects | In animal studies, no adverse effects on male or female fertility were observed at exposures up to 0.5 times the human AUC. No human data on fertility are available. The drug does not appear to impair gonadal function or gametogenesis based on preclinical evidence. Reversibility of any effect is presumed. |